Oxford’s recovery trial to evaluate REGN-COV2 for COVID-19 treatment
Category: #health  By Nikita Chaurasia  Date: 2020-09-16
  • share
  • Twitter
  • Facebook
  • LinkedIn

Oxford’s recovery trial to evaluate REGN-COV2 for COVID-19 treatment

According to credible sources, the University of Oxford has announced that it will be initiating the Recovery Trial for testing REGN-COV2, an experimental drug developed for the treatment of the COVID-19 virus.

Sources with relevant information stated that a batch of COVID-19 patients in most of NHS (National Health Service) acute hospitals will be randomly subjected to the testing of the novel drug.

For the record, REGN-COV2 has been developed by U.S.-based Regeneron Pharmaceuticals Inc. by combining two human antibodies that neutralize the mutant viruses. The company had previously developed a similar drug against the Ebola virus.

Unlike the initially developed dexamethasone, the new drug specifically targets the COVID-19 virus and has successfully proceeded to its last stage trials in the U.S.

Peter Horby, Chief investigator of the trial as well as a professor of emerging infectious diseases and global health at the Oxford University, was reported stating that although the university has observed positive outcomes of dexamethasone while treating COVID-19 patients, additional new drugs need to be explored to cope with the soaring death rate.

Martin Landray, a professor of medicine & epidemiology and Deputy Chief investigator of the trial expressed his enthusiasm towards the development and stated that the Recovery trial will enable vigorous assessment of REGN-COV2 among hospitalized patients.

However, experts are skeptical over the affordability of the new antibody vaccine, considering the cost of dexamethasone was around £5 to treat a patient with coronavirus.

In other news, British researchers will reportedly test inhaled COVID-19 vaccines developed by Imperial College and Oxford University. As per reliable sources, the trial is aimed at checking whether direct dosage to the respiratory tract can give a better immune response than conventional dosage methods. 

Source credits: https://www.theguardian.com/world/2020/sep/14/new-antibody-drug-added-to-oxford-university-trial-of-covid-19-treatments

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Ransomware attack cripples IT systems of United Health Services Inc.
Ransomware attack cripples IT systems of United Health Services Inc.
By Nikita Chaurasia

  The company claims that no patient records were compromised. UHS system files were being renamed with the addition of a ‘.ryk’ extension. Universal Health Services Inc. (UHS), U.S.-based leading healthcare service provider w...

New research claims sufficiency of vitamin D reduces COVID-19 severity
New research claims sufficiency of vitamin D reduces COVID-19 severity
By Nikita Chaurasia

According to a recent study, COVID-19 patients having sufficient levels of vitamin D, with at least 30 ng/mL of 25-hydroxyvitamin D in their blood, are less likely to witness severe clinical outcomes and deaths. The study, which was published by the...

Amazon adds indoor surveillance drone to security solutions portfolio
Amazon adds indoor surveillance drone to security solutions portfolio
By Nikita Chaurasia

  This is the next big launch after the announcement of car security devices Indoor drone will offer video surveillance in places devoid of static cameras U.S.-based multinational technology giant, Amazon.com Inc. along with Ring Inc. has ...